SLC5A2 and heart failure: Sodium–glucose cotransporter-2 (SGLT2) inhibitors as antihyperglycemic drugs are proven to have a cardiovascular protective effect in reducing cardiovascular death and hospitalization for heart failure (hHF) in large randomized trials [8–10].